IL1A and ovarian cancer: Using a more potent anti-inflammatory, another randomized controlled trial is underway, using bermekimab, which is a humanized antibody to IL-1α [49] and examining its effects on muscles, physical function and appetite in patients with lung, pancreatic or ovarian cancer (MICA trial).